Fierce Biotech White Logo Fierce Biotech White Logo

Accelerating PROTACS Drug Discovery with One-Stop TPD Solutions

Available on-demand
60 Minutes

Join industry experts for this webinar that will include two insightful topics of discussion!

Part 1: One-stop degrader in vitro profiling

Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. To discover such compounds, there are several challenges that need to be addressed to successfully facilitate and expedite TPD drug discovery. We’ll explore these challenges in more detail, as well as take a look at TPD platforms and how they can be effective solutions for resolving key issues.

Part 2: Chemistry synthesis service for PROTACs drug discovery

PROTACs (PROteolysis TArgeting Chimeras) have emerged as a new and promising modality in medicinal discovery, and research into their potential is currently a very active area. A PROTAC is a heterobifunctional molecule that consists of a protein-of-interest (POI) ligand and an E3 ubiquitin ligase (E3) recruiting ligand, connected by a linker. Learn more about the synthesizing of PROTAC molecules, the latest tools and strategies for making this work more efficient, and how this can lead to faster drug discovery.



Yanchun Guo

Yanchun Guo received her PhD from Ulm University in Germany and completed her postdoctoral training at the City of Hope National Medical Center in the US. With extensive experience in gene editing and cancer biology, Yanchun Guo joined BioDuro-Sundia in 2019 and established an in vitro evaluation platform for PROTAC drug discovery from scratch. The TPD platform, led by Yanchun, has received high recognition from many clients, including Pfizer.


Xingao Peng

Xingao Peng received his PhD from the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences in 2008, and then completed postdoctoral training at Colorado State University in the US and Nanyang Technological University in Singapore. With extensive experience in synthetic chemistry, Dr. Peng joined BioDuro-Sundia in 2015, where he focused on medicinal chemistry, particularly with a strong emphasis on the chemistry synthesis of PROTACs for drug discovery.

Register here to watch on-demand!

60 Minutes